Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
211.90
-0.83 (-0.39%)
Jun 3, 2026, 1:12 PM EDT - Market open
Natera Revenue
Natera had revenue of $696.64M in the quarter ending March 31, 2026, with 38.82% growth. This brings the company's revenue in the last twelve months to $2.50B, up 36.59% year-over-year. In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth.
Revenue (ttm)
$2.50B
Revenue Growth
+36.59%
P/S Ratio
12.18
Revenue / Employee
$407,317
Employees
6,140
Market Cap
30.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.98% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.63B |
| Labcorp Holdings | 14.14B |
| Quest Diagnostics | 11.28B |
| Agilent Technologies | 7.23B |
| IDEXX Laboratories | 4.45B |
| Illumina | 4.39B |
| Mettler-Toledo International | 4.09B |
| Waters | 3.77B |
NTRA News
- 4 hours ago - Natera appoints Lynch, Rubin to board of directors - TheFly
- 5 hours ago - Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - Business Wire
- 1 day ago - Natera assumed with an Outperform at Wolfe Research - TheFly
- 2 days ago - CareDx denied request to Supreme Court to revive Natera award - TheFly
- 5 days ago - Natera announces collaboration with Diakonos Oncology for Signatera in RM - TheFly
- 5 days ago - Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma - Business Wire
- 6 days ago - Natera enrolls first patients in SIGNAL-ER 101 study - TheFly
- 6 days ago - Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer - Business Wire